Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | HCK | P08631 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676973 | 1.00 | PIK3C3 (0.39) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL3196822 | 0.77 | TGFBR1 (0.54) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL3185826 | 0.76 | PIK3C3 (0.45) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL3323702 | 0.74 | PIK3C3 (0.39) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL14826051 | 0.74 | PIK3C3 (0.51) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL9380855 | 0.73 | PIK3C3 (0.48) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL1431511 | 0.73 | KDR (0.45) | KDRFGFR3 | |
| SCHEMBL3189520 | 0.72 | KDM4E (0.43) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL3190030 | 0.72 | PIK3C3 (0.39) | PIK3C3KDRABL1PIK3CDEGFR | |
| SCHEMBL29707258 | 0.72 | PIK3CD (0.41) | PIK3C3KDRABL1PIK3CDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717471-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | PIK3C3 313/4885KDR 264/4885ABL1 1603/4885 |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | PIK3C3 131/4885KDR 50/4885ABL1 1/4885 |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | JAK3, IFNG, IL23R | PIK3C3 256/4885KDR 303/4885ABL1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.